Major New Risk Management Burden Coming Under Part 11 Revision

Drug GMP Report
KEYWORDS Part 11 / Technology

The FDA’s long-awaited revision of Part 11, which is now slated for release this year, will impose major new burdens on industry in the area of risk assessment and management, according to Martin Browning, president of EduQuest and a former FDA official.

To View This Article:


Subscribe To Drug GMP Report

Buy This Article Now

Add this article to your cart for $10.00